Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04905069 · ClinicalTrials.gov registry record · NA
Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer
A NA study of Prostate Cancer, sponsored by Boston Scientific Corporation.
- Active
- Registry status
- NA
- Development phase
- 500
- Enrollment target
- 20
- Study locations
NCT04905069: Active NA study of Prostate Cancer, sponsored by Boston Scientific Corporation.
NCT04905069 is a NA study of Prostate Cancer that is active but no longer recruiting, run by Boston Scientific Corporation. The registered enrollment target is 500 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (18% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04905069, a NA study of Prostate Cancer, is active but no longer recruiting, sponsored by Boston Scientific Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
To demonstrate the effectiveness of the SpaceOAR Vue System in reducing late gastrointestinal (GI) toxicity in subjects undergoing Stereotactic Body Radiotherapy (SBRT) to treat prostate cancer.
Primary Outcome
Proportion of subjects experiencing late GI toxicity after SBRT treatment with or without placement of the SpaceOAR Vue System hydrogel. Late GI toxicity is defined as the occurrence of a Grade 2 or greater GI adverse event (NCI CTCAE v4) between 3- and 24-months post-SBRT initiation
Conditions Studied
Interventions
- DEVICE SpaceOAR Vue System
Study Locations (20)
Other
- Institut de Radiothérapie & Radiochirurgie HARTMANN - Levallois-Perret
- MEDICLIN Robert Janker Klinik - Bonn
- Klinikum Nurnberg Nord - Nuremberg
- Bon Secours Radiotherapy Cork - Cork
- Azienda Ospedaliero Universitaria di Parma - Parma
- Policlinico Universitario Agostino Gemelli - Rome
- IRCCS Ospedale Sacro Cuore Don Calabria - Verona
- Hospital Universitario Cruces - Barakaldo
- GenesisCare, Hospital San Francisco de Asis - Madrid
Florida
- GenesisCare USA - Fort Myers
- Florida Urology Partners, LLC - Tampa
Kansas
- Kansas University Medical Center - Kansas City
Michigan
- GenesisCare USA - Troy
New Jersey
- New Jersey Urology, a Summit Health Company - Bloomfield
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
South Carolina
- Dr. John Sylvester - Myrtle Beach
New South Wales
- Calvary Mater Newcastle - Waratah
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2021-12-21 |
| Est. Completion | 2030-04 |
| Phase | NA |
What the registry record for NCT04905069 still lists
NCT04905069 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (18% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which SpaceOAR Vue System is the first listed.
NCT04905069 names 20 study sites across 11 states, led by Other, Florida, Kansas.
Frequently Asked Questions
What is clinical trial NCT04905069 about?
NCT04905069 is a clinical study titled "Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer". To demonstrate the effectiveness of the SpaceOAR Vue System in reducing late gastrointestinal (GI) toxicity in subjects undergoing Stereotactic Body Radiotherapy (SBRT) to treat prostate cancer.
What is the current status of trial NCT04905069?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 500 participants. The study started on 2021-12-21. Estimated completion is 2030-04.
What conditions does trial NCT04905069 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT04905069?
The interventions under investigation include: SpaceOAR Vue System (DEVICE).
Who is sponsoring clinical trial NCT04905069?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04905069 being conducted?
This trial has 20 study locations across Florida, Kansas, Michigan, New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04905069's enrollment target sits among peer trials
500 105th of 735 higher than 623 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI